APLT

Applied Therapeutics, Inc. (APLT) | Rumor.io

Applied Therapeutics

APLT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)80%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about APLT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 30

NASDAQ trading halt for $APLT has been initiated pending information request from the company, with potential volatility anticipated upon resumption.
The halt is expected to continue until official confirmation is received, and traders are advised to exercise caution and monitor support levels closely.
If enough shares are tendered, the deal will close on February 3, and $APLT will remain halted until February 4, with shareholders receiving $0.088 and a CVR per share.

Generated by AI

Sentiment

Of the messages about APLT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.09% +10.05
Bearish	—	—	—	9.91% -10.05

Bullish· Dec 24

$APLT has the potential for a 500% price increase due to an extreme low float and a potential squeeze.
The stock is expected to follow the trend of $OMER, and may experience a significant price increase soon.
$APLT is undervalued and has the potential for a 300-1000% price increase, with a lowest analyst estimate of $1.5 and a highest estimate of $13.

Bearish· Dec 12

The company's acquisition price of $0.088 per share is a significant decline from its previous highs.
The acquisition deal may fall apart due to the buyer's potential realization that the company's drug is not viable, as it has failed every test.
The company's former CEO, Shoshana Shendelman, is accused of misleading investors and making millions of dollars while selling shares, which may have contributed to the company's downfall.

Generated by AI

Topics

Of the messages about APLT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	23.23%
Macro	—	—	0%	25.52%
Earnings	—	—	0%	1.59%
Controversies	—	—	0%	4.27%
Announcements	—	—	100%	17.94%
Analysts	—	—	0%	27.44%

Announcements· Dec 12

Applied Therapeutics, Inc. ($APLT) has been acquired by Cycle Group Holdings for $0.088 per share in cash, plus a non-transferable contingent value right (CVR) potentially worth up to $0.40 per share.
The CVR provides payments based on FDA approval of new drug applications for galactosemia and CMT-SORD indications, as well as worldwide net sales of products covered by the CVR.
The acquisition provides a path forward for Applied Therapeutics' lead asset govorestat, a CNS-penetrant ARI targeting rare metabolic diseases, and is expected to close in early 2026.

Technical Analysis· Sep 26

$APLT has broken through resistance with high volume, sending the RSI into overbought territory and indicating a strong bullish momentum.
The stock has been identified as a potential break-out candidate, with a target price of $1.27 and a need for strong follow-through to overcome historical volatility.
$APLT has experienced a significant price surge, up 82% intraday, on FDA news and a lawsuit settlement, with the stock currently trading near $1.00 and showing signs of a potential flush-and-reset formation.

Generated by AI

Community

Of the messages about APLT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	42.49%
Newcomers	—	—	100%	57.51%

Regulars· Dec 12

Cycle Pharmaceuticals is acquiring Applied Therapeutics, Inc. (APLT) in a tender offer at $0.088 per share in cash plus a non-transferable contingent value right (CVR) tied to future milestones.
The CVR has a potential payout of up to $0.40 per share based on FDA approvals and sales, with a closing expected in early 2026.
Applied Therapeutics' lead asset, govorestat, a CNS-penetrant aldose reductase inhibitor targeting rare metabolic diseases, will continue to be developed under the new ownership.

Newcomers· Nov 18

$APLT is experiencing a surge, with a 5.9% increase in the last hour.
Newcomers are focusing on the FDA's potential impact on Applied Therapeutics, Inc.'s stock, with some users referencing it with a 💎FDA symbol.
Analysts have updated their price target for $APLT, but the exact target is not specified.

Generated by AI

Amarin (AMRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

2mo agoYahoo Finance

Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SL1009, sodium dichloroacetate (DCA), for the treatment of pyruvate dehydrogenase complex deficiency (PDCD), a rare, life-threatening mitochondrial disease with no FDA-approved therapies.

2mo agoYahoo Finance

Also Discussed

Investors talking about APLT also mention

#	Name	Attention
1	SWTX - SpringWorks Therapeutics, Inc.	——
2	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
3	ETNB - 89bio, Inc.	——
4	Shattuck Labs, Inc.STTK	0%new
5	Keros Therapeutics, Inc.KROS	0%new
6	TERN - Terns Pharmaceuticals, Inc.	——
7	TNL Mediagene Ordinary SharesTNMG	0%new
8	Acumen Pharmaceuticals, Inc.ABOS	0%new
9	Olema Pharmaceuticals, Inc.OLMA	0%new
10	GoHealth Inc.GOCO	0%0